Previous 10 | Next 10 |
Gainers: Bit Digital (BTBT) +51%.Infinity Pharmaceuticals (INFI) +46%.NanoVibronix (NAOV) +40%.Tilray (TLRY) +26%.Flora Growth Corp. (FLGC) +25%.Youdao (DAO) +24%.Grove (GRVI) +22%.Zhangmen Education (ZME) +23%.First High-School Education (FHS) +22%.Canaan (CAN) +21%.Losers: Hoegh LNG Partner...
Gainers: Infinity Pharmaceuticals (INFI) +62%, Grove (GRVI) +26%, Shineco (TYHT) +24%, Tilray TLRY +22%, NeuroMetrix (NURO) +19%.Losers: Dyadic (DYAI) -14%, EyeGate Pharmaceuticals (EYEG) -13%, NanoViricides (NNVC) -13%, Myovant Sciences MYOV&...
Hoegh LNG Partners LP (HMLP) -63% slashes dividend by ~98% to $0.01 per share.Alset EHome International Inc. (AEI) -34% after secures $32M capital raiseSGOCO Group, Ltd. (SGOC) -11%.Teladoc Health, Inc. (TDOC) -9% on Q2 earnings releaseXenetic Biosciences, Inc. (...
Gainers: Intrusion (INTZ) +65%.MOGU (MOGU) +40%.Oragenics (OGEN) +32%.BiondVax Pharmaceuticals (BVXV) +29%.Sintx Technologies (SINT) +23%.Dyadic International (DYAI) +21%.EyeGate Pharmaceuticals (EYEG) +19%.U.S. Physical Therapy (USPH) +18%.ObsEva SA (OBSV) +16%.Orbsat (OSAT) +15%.Losers: IRS...
Gainers: Oragenics OGEN +58%, EyeGate Pharmaceuticals (EYEG) +54%, Dyadic DYAI +29%, ObsEva OBSV +27%, U.S. Physical Therapy (USPH) +15%.Losers: Infinity Pharmaceuticals INFI -30%, NanoVibronix (NAOV) -22%, ATI Physical Therapy (ATIP...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The share price of EyeGate Pharmaceuticals (NASDAQ: EYEG ) stock has more than doubled at Tuesday’s market open after the clinical-stage eye-disease-treatment developer said it intends to acquire Bayon Th...
Delmaine Donson/E+ via Getty Images EyeGate Pharmaceuticals (EYEG) announces the appointment of Brian Strem as the company's president and chief executive officer. Additionally, EyeGate has entered a non-binding letter of intent to acquire privately held Bayon Therapeutics for ...
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the e...
- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021- WALTHAM, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and c...
AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...